Drugs / Trivalent Influenza Vaccine (TIV-1)
Trivalent Influenza Vaccine (TIV-1)
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02214225 Comparator | Aug → Nov 2014 | influenza | Seqirus | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trivalent Influenza Vaccine (TIV-1) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02214225 ↗ |
| Known as | bioCSL TIV-1 | “a US licensed 2014/2015 trivalent influenza vaccine (bioCSL TIV-1)” NCT02214225 ↗ |
| Known as | CSL TIV-1 | “a US Licensed 2014/2015 Trivalent Influenza Vaccine (CSL TIV-1)” NCT02214225 ↗ |
| Modality | Vaccine | “a US licensed 2014/2015 trivalent influenza vaccine (bioCSL TIV-1)” NCT02214225 ↗ |
| Route | Intramuscular | “One 0.5 mL intramuscular dose into the deltoid muscle.” NCT02214225 ↗ |